Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year.
Suayib Yalcin
No relevant relationships to disclose
Suleyman Buyukberber
No relevant relationships to disclose
Ugur Yilmaz
Honoraria - Honoria for specific speeches and advisory board meetings
Research Funding - Grants for participating to multicenter trials
Po-Huang Lee
No relevant relationships to disclose
Vichien Srimuninnimit
No relevant relationships to disclose
Pin-Wen Lin
No relevant relationships to disclose
Mostafa M. Elserafy
No relevant relationships to disclose
Moustafa Manieh
No relevant relationships to disclose
Patrapim Sunpaweravong
Consultant or Advisory Role - advisory board
Honoraria - Speaker
Other Remuneration - conference attendance
Yuriy Istomin
No relevant relationships to disclose
Virote Sriuranpong
No relevant relationships to disclose
Tsann-Long Hwang
No relevant relationships to disclose